The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Deinduction of P-glycoprotein resulting in delayed viral response during hepatitis C treatment
J Clin Pharm Ther. 2021 Feb 3. doi: 10.1111/jcpt.13374. Online ahead of print.
Jennifer E Stark1, Jennifer L Cole1
Author information
1Department of Pharmacy, Veterans Health Care System of the Ozarks, Fayetteville, AR, USA.
Abstract
What is known and objective: Drug-drug interactions can involve inhibition or induction of cell membrane transporters. Deinduction occurs after an inducing agent is stopped.
Case summary: This case describes suspected P-glycoprotein (P-gp) deinduction by carbamazepine resulting in a slow viral response during treatment of chronic hepatitis C virus (HCV) infection. Evidence of deinduction occurred beyond clearance of carbamazepine and resulted in extension of HCV treatment.
What is new: The understanding of the role P-gp transport plays in drug elimination is relatively new and evidence of P-gp deinduction is variable.
Conclusion: Clinicians should consider deinduction when starting and stopping medications involving strong inducers of P-gp transport proteins.